Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and ...
Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...
Staff at the US Federal Trade Commission said it appears Novo Nordisk A/S’ proposed bid for Metsera Inc. “may violate the ...
Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...
Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's ...
The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...
Novo Nordisk stock just crashed -- but new drugs, smart acquisitions, and Wall Street upgrades could set up one of the ...
Discover how Novo Nordisk's pipeline is being restructured to refocus its efforts on high-growth areas like diabetes and ...
Wegovy maker Novo Nordisk said on Wednesday that its executive vice president in charge of manufacturing was stepping down.
Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback